Company shares climbed by more than 20% on Phase 2 study results suggesting the therapy could provide sustained relief when ...
An experimental treatment for eczema from Apogee Therapeutics induced skin and itch relief comparable to current, widely used ...
On Friday, the U.S. Food and Drug Administration approved Eli Lilly's eczema drug for use in adults and children 12 and older. The medication is an injectable branded Ebglyss and will be available in ...
A recently approved injectable eczema drug provides quick itch relief to patients with the maddening skin disease, a new study says. Nemolizumab (Nemluvio) relieved itchiness within two days for three ...
--New results show Eli Lilly and Company's EBGLYSS achieved deep and sustained response for patients with moderate-to-severe atopic dermatitis at three years. These findings from the ADjoin long-term ...
Please provide your email address to receive an email when new articles are posted on . Ebglyss is a targeted interleukin-13 inhibitor approved for the treatment of moderate-to-severe atopic ...
Phase 3 data show lebrikizumab improves skin clearance and itch in children with moderate to severe atopic dermatitis, ...
Eli Lilly’s phase 3 ADorable-1 trial of Ebglyss in paediatric patients with moderate-to-severe atopic dermatitis meets primary and key secondary endpoints: Indianapolis Tuesday, ...
MOH said it will provide an update when it is ready, with a decision expected to be made in 2026. Read more at ...
I'm a beauty editor who's tried just about every product, and these creams are my go-to's.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results